FDA Lotronex Letter Cites Desire To Work With Glaxo To Maintain Therapy

FDA is willing to continue working with Glaxo Wellcome on a risk management program for Lotronex, the agency said in a Dec. 18 letter to consumers.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet